echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > National talks closing day: CAR-T corporate representatives did not show up, PD-1 "F4" stock prices fell

    National talks closing day: CAR-T corporate representatives did not show up, PD-1 "F4" stock prices fell

    • Last Update: 2021-12-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On November 11, the 2021 national medical insurance drug catalog entry negotiations ended, and the secondary market has returned to calm
    .
    Compared with the previous day's domestic PD-1 "F4" share price "started in place", at the close of trading today, the share prices of Cinda Bio, Junshi Bio, and BeiGene all fell more than 5%, and Hengrui Pharmaceuticals fell 1.
    36%
    .
    The medical insurance negotiations that began in 2016 have now become the "year-end test" for pharmaceutical companies
    .
    The new medical insurance catalogue is coming soon, what new drugs will enter? What kind of changes will take place in the market competition landscape? Does the enterprise choose to exchange price for volume or compensate for volume? Become the most concerned issue of the industry
    .
    Millions of CAR-T companies did not show up.
    It is understood that the negotiation on the National Medical Insurance Catalogue lasts for 3 days and is divided into disease areas.
    The first two days of negotiations centered on the large variety of drugs used in the treatment fields such as tumors, mental diseases, and antivirals.
    The last day of negotiations The main varieties are gynecological, cardiovascular, blood, children and dermatological drugs
    .
    In this medical insurance negotiation, Fosun Kate's Akirenzine injection is undoubtedly one of the most concerned drugs
    .
    As China's first CAR-T product, the drug is highly concerned about whether it can enter the medical insurance catalog because of its high price of 1.
    2 million yuan per injection
    .
    However, according to The Paper, as of more than four o'clock in the afternoon on November 11, no representative of Fosun Kate had been seen at the scene, and the Akirenseed injection might not have entered the negotiation
    .
    Previously, the drug appeared in the 2021 medical insurance catalog adjustment and passed the preliminary formal review of the drug catalog
    .
    However, passing the preliminary formal review does not necessarily mean that it will enter medical insurance negotiations
    .
    The National Medical Insurance Bureau pointed out that some of the more expensive drugs passed the preliminary formal review, which only indicated that the drug met the application requirements after the preliminary review and was qualified to enter the next adjustment link
    .
    If Fosun Kate did not participate in this negotiation, it means that Akilenseal injection entered the preliminary list, but failed to enter the real negotiation link due to other reasons.

    .
    CAR-T cell therapy is an emerging treatment method.
    There are currently two CAR-T products approved in China, one is Fosun Kate’s Akirensai injection, and the other is WuXi Juno’s Ruiqiolun.
    Match injection
    .
    However, according to the medical insurance negotiation rules, participating products need to be approved for listing before June 30, so the products approved by WuXi Juno in September are not eligible for this negotiation
    .
    The outside world generally believes that, without competition, considering that CAR-T therapy is a tailor-made personalized medicine, there are very high requirements from the collection and transportation of cells to the cultivation, storage, and quality control of the entire technical backstage.
    It is difficult to significantly reduce its preparation cost, and it is expected that it is unlikely to enter medical insurance with a substantial price cut
    .
    In recent years, 20 domestically-made innovative drugs have been on the market.
    In recent years, the domestic innovative drug industry has developed vigorously.
    However, due to the complex competitive landscape in the industry, it has become the unanimous choice of domestic pharmaceutical companies to accelerate the drug volume with the help of medical insurance.
    The directory advances
    .
    The data shows that 93.
    02% of the non-catalog products that passed the preliminary formal review this year are new drugs that will be on the market after 2016
    .
    According to CCTV reports, there are 20 domestically-made innovative drugs for the first time in the national talks
    .
    After sorting out, they come from Hengrui Pharmaceuticals, BeiGene, Rongchang Biologics, Hutchison Pharmaceuticals, Betta Pharmaceuticals, Hansen Pharmaceuticals, Fosun Kate, Nuocheng Jianhua, Haisco, Zejing Pharmaceuticals, Simcere Pharmaceuticals, Ellis, the cornerstone of medicine, and other
    .
    It is reported that representatives of Rongchang Biological Enterprise appeared at the negotiation site today, and the company's taltacept and vedicitumumab are the drugs that participated in the medical insurance negotiations for the first time
    .
    Vidicituzumab is the first domestically developed ADC drug.
    At present, only two HER2-ADCs of Rongchang Biologics' Vidicituzumab and Roche's Enmetrastuzumab have been approved for marketing in the domestic market
    .
    The two approved indications are different.
    The former is used for gastric cancer and the latter is used for breast cancer.
    Therefore, the short-term competition pattern is good
    .
    Essence Securities predicts that in this national talks, the drop rate of vedicitumumab is expected to reach 50% to 60%
    .
    It is worth noting that vedicitumumab was approved for listing in June this year, and it went to sea smoothly after two months: Rongchang Biotechnology and NASDAQ-listed Seattle Genes signed a global exclusive agreement on the development and commercialization of the drug License agreement
    .
    According to the agreement, Rongchang Bio will obtain a total potential income of up to 2.
    6 billion US dollars, which sets a new record for single-drug "License-out"
    .
    According to forecast data, the market size of China's ADC drug industry will grow from 4.
    2 billion yuan in 2020 to 12.
    6 billion yuan in 2024, with a compound annual growth rate of 31.
    6%
    .
    Facing the market potential of ADC drugs, according to incomplete statistics, there are now more than 20 domestic companies in China, such as Hengrui Pharmaceutical, CSPC, Kelun Pharmaceutical, Junshi Biological, Zhejiang Pharmaceutical, Biotech, Toyao Pharmaceutical and Shanghai and other beauty Yake
    .
    Biotech’s BAT8001 and Toyo Pharmaceutical’s TAA013 are in the rapid progress of research and development, which are already in phase 3 clinical trials
    .
    The smoke of PD-1 has risen again, and the internal volume is still the same.
    Compared with the previous day, many oncology drug companies gathered to chase and intercept the reporters.
    Today, the number of business representatives and reporters participating in the negotiations has decreased, and the popularity has declined
    .
    In this view, in this medical insurance negotiation, the anti-tumor drug PD-1 monoclonal antibody is still the focus of the industry
    .
    According to the preliminary review list of the 2021 version of the medical insurance catalogue, multinational companies Merck’s pembrolizumab, BMS’s nivolizumab, and AstraZeneca’s duvalizumab are all on the list, and 4 domestic companies that have been approved for new indications All PD-1 products have entered the preliminary review list
    .
    Before the end of June this year, Junshi Biotech’s teriprizumab injection has added 2 indications, Xinda Bio’s Sintilizumab injection has added 3 indications, and Hengrui Medicine’s injection card Relilizumab has two new indications, BeiGene's tislelizumab injection has three new indications.
    The acquisition of new indications will also make the PD-1/L1 market face more complicated competition Pattern
    .
    Recently, as the price of Sepalizumab was exposed-the retail price of 120mg (4ml)/bottle was 3,300 yuan, the price of domestic PD-1 was refreshed again.

    .
    Such a low-price entry has triggered a big discussion in the industry
    .
    From the perspective of the industry, the PD-1 price dispute will once again become fierce, which may give the medical insurance negotiation system more reasons to bargain, and the PD-1 "Warring States Era" will fight more fiercely
    .
    Some people point out that the pricing of medicines is related to medical insurance, patients' ability to pay, and the enthusiasm of pharmaceutical companies for research and development
    .
    As a weather vane for biological drugs, the future competition of PD-1 drugs in the adjustment of the medical insurance catalogue is not entirely a price war.
    After the price is reduced to a certain extent, the coverage of indications and the supply of capacity will become new dimensions of competition
    .
    In the 2020 medical insurance negotiations, the PD-1 drugs of Hengrui Pharmaceuticals, Cinda Biologics, BeiGene and Junshi Biologics were included in the medical insurance catalog with a decrease of 85.
    21%, 63.
    73%, 79.
    60%, and 70.
    82%, respectively, and the overall decrease was up to 60%~85%
    .
    The price reduction of domestically produced PD-1 products has also led to a decline in the price of imported PD-1/L1.
    Therefore, in addition to domestically produced PD-1, the amount of imported PD-1/L1 products that can be reduced this time has also attracted much attention
    .
    According to on-site reports from Sina Pharmaceuticals, both AstraZeneca and Merck should have attended the PD-1/L product negotiation
    .
    Industry insiders previously predicted that multinational pharmaceutical companies' products would lack motivation to participate in medical insurance negotiations, and the enthusiasm for lowering prices to enter the medical insurance catalog was not high
    .
    In recent years, the domestic anti-tumor drug market has maintained a high growth rate
    .
    According to data from Mi Nei.
    com, in recent years, the sales scale of terminal anti-tumor drugs in urban public hospitals, county-level public hospitals, urban community centers, and township health centers in China has risen rapidly.
    The growth rates from 2016 to 2019 were 12.
    44%, 16.
    36%, respectively.
    19.
    10%, 21.
    30%, rose to 96.
    1 billion yuan in 2019
    .
    In the view of pharmacoeconomics, with the evolution of cancer treatment methods, more and more cancer patients are living with tumors for a long time, and tumors are becoming chronic diseases like hypertension, which brings challenges to the existing value assessment
    .
    Therefore, how to comprehensively measure the value of innovative drugs is also a challenge for pharmacoeconomics
    .
    The final result of this medical insurance negotiation is still to be officially announced
    .
    According to the 2021 National Medical Insurance Drug List Adjustment Work Plan, September to October is the negotiation stage, and October to November is the announcement stage
    .
    Actually, the negotiation time has been slightly delayed, and it remains to be seen whether the results will be announced as scheduled
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.